Trial Profile
A study of Hu5F9-G4 in combination with atezolizumab in patients with bladder cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 12 Jan 2018
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Magrolimab (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech
- 12 Jan 2018 New trial record